Lung deposition via different inhalation devices

Study identifier:D5252M00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I, randomized, open-label, 5-way crossover, single centre study in healthy subjects to assess the lung deposition of inhaled budesonide delivered via different inhalation devices

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Pulmicort pMDI HFA, Budesonide pMDI HFA, Pulmicort Repulses, Pulmicort Turbohaler

Sex

All

Actual Enrollment

16

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Sept 2009
Primary Completion Date: -
Study Completion Date: 01 Nov 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria